Patent search ap:("Merck Sharp & Dohme Corp.") AND inv:"Hong Li" Page 2

11.

发明申请
Factor IXa Inhibitors 审中-公开

公开(公告)号：US20180022747A1

公开(公告)日：2018-01-25

申请号：US15550862

申请日：2016-02-12

Applicant: Dongfang MENG , Hong LI , Meng YANG , Manuel de Lera RUIZ , Sunita V. DEWNANI , Tianying JIAN , Dann L. PARKER, JR. , Ting ZHANG , Louis-Charles CAMPEAU , Bart HARPER , Harold B. WOOD , Jiayi XU , Richard BERGER , Jane Yang WU , Robert K. ORR , Shawn P. WALSH , Merck Sharp & Dohme Corp.

Inventor： Dongfang Meng , Hong Li , Meng Yang , Manuel de Lera Ruiz , Sunita V. Dewnani , Tianying Jian , Dann L. Parker, Jr. , Ting Zhang , Louis-Charles Campeau , Harold B. Wood , Jiayi Xu , Richard Berger , Jane Yang Wu , Robert K. Orr , Shawn P. Walsh , Bart Harper

IPC: C07D471/04 , C07D403/12 , C07D498/04 , C07D417/14 , C07D513/04 , C07D471/14 , C07D413/14

CPC classification number: C07D471/04 , A61P9/00 , C07D403/12 , C07D413/14 , C07D417/14 , C07D471/14 , C07D498/04 , C07D513/04

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

12.

发明申请
SPIROCYCLIC CETP INHIBITORS 有权
Title translation: 螺旋类CETP抑制剂

公开(公告)号：US20150342931A1

公开(公告)日：2015-12-03

申请号：US14653445

申请日：2013-12-17

Applicant: MERCK SHARP & DOHME CORP.

Inventor： Debra Ondeyka , Xiaoxia Qian , Petr Vachal , Sriram Tyagarajan , Cameron J. Smith , Hong Li , Jianming Bao

IPC: A61K31/423 , A61K31/4439 , C07D413/14 , A61K45/06 , A61K31/506 , A61K31/5377 , C07D263/52 , C07D413/06 , A61K31/444

CPC classification number: A61K31/423 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D263/52 , C07D413/06 , C07D413/14

Abstract: Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis.

Abstract translation: 具有式（I）结构的化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于提高人类患者的HDL-胆固醇和降低LDL-胆固醇，并用于治疗或预防动脉粥样硬化。公开了胆固醇酯转移蛋白（CETP）的化合物，并且预期可用于升高HDL-C，降低LDL-C，以及治疗和预防动脉粥样硬化。